A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study.
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Alendronic acid (Primary) ; Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 01 Dec 2015 According to ClinicalTrials.gov record, the study phase has changed from phase III to phase IV.
- 05 Nov 2010 New trial record.